Center for Advanced Studies in Agriculture and Food, KU Institute for Advanced Studies, Kasetsart University (CASAF, NRU-KU), Bangkok, Thailand.
Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand.
Reprod Domest Anim. 2021 Jul;56(7):1015-1023. doi: 10.1111/rda.13945. Epub 2021 Jun 2.
Aglepristone, a competitive progesterone antagonist, is successfully used in various progesterone-dependent conditions. This study investigated uterine histomorphometric analysis, and expressions of the oestrogen α receptor (ERα) and progesterone receptor (PR) in uteri of bitches following the single dose of aglepristone treatment. Twelve client-owned healthy diestrous bitches were used in the study. The single dose of aglepristone (Alizine , 10 mg/kg) was injected subcutaneously 5 days before ovariohysterectomy in the treatment group (n = 6); bitches without treatment served as a control group (n = 6). Uteri were collected for histomorphometric analysis, ERα and PR gene, and protein expressions studies. The mRNA expressions of ERα and PR were determined by RT-qPCR. Immunohistochemical analysis was used to evaluate the ERα and PR protein expressions using an H-score in five parts of the uterus. The results demonstrated glandular epithelium height significantly decreased (p < .05) and ERα mRNA increased (p < .01) in treated dogs. Of the treated bitches, lower expression levels of ERα were observed in the luminal epithelium, crypt and glandular epithelium, with higher expression in the endometrial stroma and myometrium (p < .05); however, PR expression decreased in the luminal epithelium, crypt and glandular epithelium (p < .01). In conclusion, reduction of the uterine glandular epithelium and ERα mRNA upregulation together with changes in ERα and PR expressions were observed in the treated bitches. However, changes in uterine ERα and PR expressions in the treated bitches depended on tissue layers. The treatment had no effect on serum oestradiol and progesterone levels.
阿格来司酮是一种竞争性孕激素拮抗剂，已成功用于各种孕激素依赖性疾病。本研究旨在探讨单次给予阿格来司酮后犬子宫的组织形态学分析以及雌激素 α 受体（ERα）和孕激素受体（PR）的表达情况。本研究使用了 12 只来自客户的健康发情期母犬。在治疗组（n=6）中，母犬在卵巢子宫切除术前 5 天经皮下注射单次剂量的阿格来司酮（Alizine，10mg/kg）；未接受治疗的母犬作为对照组（n=6）。收集子宫进行组织形态学分析、ERα和 PR 基因及蛋白表达研究。通过 RT-qPCR 测定 ERα 和 PR 的 mRNA 表达。免疫组织化学分析用于使用 H 评分评估子宫中 5 个部位的 ERα 和 PR 蛋白表达。结果表明，治疗犬的腺上皮高度显著降低（p<.05），ERα mRNA 增加（p<.01）。在治疗犬中，观察到 ERα 在腔上皮、隐窝和腺上皮中的表达水平较低，在子宫内膜基质和子宫肌层中的表达水平较高（p<.05）；然而，PR 在腔上皮、隐窝和腺上皮中的表达降低（p<.01）。总之，在接受治疗的母犬中，观察到子宫腺上皮减少和 ERα mRNA 上调，同时 ERα 和 PR 表达发生变化。然而，治疗犬子宫 ERα 和 PR 表达的变化取决于组织层。该治疗对血清雌二醇和孕酮水平没有影响。
